Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (3506)	6/12/1998 5:58:00 PM
From: zurdo	Read Replies (1) \| Respond to of 9523

Anthony, was it a call-in type of interview, and if so did anyone ask him about Pfizer??

To: Anthony Wong who wrote (3506)	6/12/1998 6:52:00 PM
From: DT	Read Replies (1) \| Respond to of 9523

Anthony, I am new to the thread but always appreciate your posts. I work in the pharmacy benefits industry and can confirm that we advise our clients that their drug spend will be increasing 10-20% per year for the next 3-5 years due to increased utilization, inflation (prices), and intensity (substituting higher price new medications for older, less expensive products). The quantity of new products that will be entering the market in the next 5 years will also exceed savings generated from brand drugs going to generics for the first time in recent history. Good news for pharmaceutical companies, somewhat bad news for health plans. As to Viagra coverage, this is one of the biggest concerns for many of our clients at the moment. Many plans are facing significant pressure from members to cover Viagra.